• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Barinthus Biotherapeutics plc - American Depositary Shares (NQ:BRNS)

0.6300 UNCHANGED
Streaming Delayed Price Updated: 12:52 PM EDT, May 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Barinthus Biotherapeutics plc - American Depositary Shares

< Previous 1 2 Next >
News headline image
Halper Sadeh LLC is Investigating Whether TBRG, SILA, BRNS are Obtaining Fair Deals for their Shareholders
April 30, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
April 30, 2026
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments
March 13, 2026
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
December 10, 2025
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages HFWA, BRNS, FITB Shareholders to Contact the Firm to Discuss Their Rights
November 20, 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages HFWA, FITB, AVDL, BRNS Shareholders to Contact the Firm to Discuss Their Rights
November 18, 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
November 07, 2025
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
October 16, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates DAY, BRNS, ETNB, VRNT on Behalf of Shareholders
October 08, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
October 08, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VECO, BRNS, VRNT on Behalf of Shareholders
October 04, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
October 03, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
BRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Barinthus Biotherapeutics plc Is Fair to Shareholders
September 30, 2025
From Halper Sadeh LLC
Via Business Wire
News headline image
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
September 30, 2025
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments
August 07, 2025
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Q2 Virtual Investor Summit: Presentations Available Now
June 25, 2025
Via ACCESS Newswire
News headline image
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
June 09, 2025
Via ACCESS Newswire
News headline image
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
May 07, 2025
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
March 20, 2025
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
March 18, 2025
Via ACCESS Newswire
News headline image
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
March 06, 2025
Via ACCESS Newswire
News headline image
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
January 10, 2025
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
November 25, 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
November 15, 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
November 15, 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
November 06, 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
October 31, 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
October 01, 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
September 24, 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
August 08, 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap